Stoke Therapeutics, Inc.
STOK- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001623526
In the last 90 days, Stoke Therapeutics, Inc. insiders filed 0 open-market purchases and 7 sales; 197 institutions reported holding it in 13F filings for Q2 2026, worth $2.49B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:19 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $6.88M (3.7% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Mar 18, 2025 | Mar 25, 2024 | Mar 6, 2023 | Jan 10, 2022 |
| Revenue | $184.4M | $36.6M | $8.78M | $12.4M | – |
| Operating expenses | $205.0M | $137.9M | $123.6M | $116.8M | $86.1M |
| Research and development | $137.9M | $89.1M | $82.2M | $77.8M | $54.2M |
| Selling, general and administrative | $67.1M | $48.8M | $41.3M | $38.9M | $31.9M |
| Operating income | -$20.6M | -$101.4M | -$114.8M | -$104.4M | -$86.1M |
| Interest expense | $9.00K | $26.0K | – | – | – |
| Income tax | $0 | – | – | – | – |
| Net income | -$6.88M | -$89.0M | -$104.7M | -$101.1M | -$85.8M |
| EPS, basic | $-0.12 | $-1.65 | $-2.38 | $-2.60 | – |
| EPS, diluted | $-0.12 | $-1.65 | $-2.38 | $-2.60 | – |
| Weighted shares, basic | 59.2M | 54.0M | 44.0M | 38.9M | – |
| Weighted shares, diluted | 59.2M | 54.0M | 44.0M | 38.9M | – |
| Margins and growth | |||||
| Operating margin | -11.2% | -277.3% | -1307.2% | -841.2% | – |
| Net margin | -3.7% | -243.4% | -1192.5% | -814.7% | – |
| Revenue growth, year over year | +404.5% | +316.3% | −29.2% | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Mar 18, 2025 | Mar 25, 2024 | Mar 6, 2023 | Jan 10, 2022 |
| Cash and equivalents | $84.2M | $128.0M | $191.4M | $113.6M | $144.9M |
| Accounts receivable | $5.94M | – | – | – | – |
| Total current assets | $305.7M | $232.8M | $215.3M | $244.1M | $229.2M |
| Property, plant and equipment | $3.15M | $3.91M | $5.82M | $6.67M | $4.14M |
| Total assets | $418.4M | $271.6M | $228.3M | $256.1M | $238.9M |
| Accounts payable | $4.94M | $2.50M | $1.70M | $766.0K | $2.38M |
| Total current liabilities | $57.9M | $40.1M | $30.8M | $31.4M | $17.1M |
| Total liabilities | $66.0M | $42.5M | $68.8M | $71.2M | $21.1M |
| Shareholders' equity | $352.5M | $229.0M | $159.6M | $184.8M | $217.8M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Mar 18, 2025 | Mar 25, 2024 | Mar 6, 2023 | Jan 10, 2022 |
| Operating cash flow | $45.6M | -$86.9M | -$81.1M | -$31.9M | -$66.9M |
| Capital expenditures | $670.0K | $203.0K | $1.62M | $3.96M | $1.20M |
| Free cash flow | $44.9M | -$87.1M | -$82.7M | -$35.8M | -$68.1M |
| Stock-based compensation | $32.2M | $27.5M | $25.3M | $22.9M | $16.4M |
| Investing cash flow | -$186.8M | -$107.5M | $105.9M | -$45.9M | -$76.4M |
| Financing cash flow | $97.4M | $131.1M | $53.0M | $46.4M | $1.28M |
| Net change in cash | -$43.8M | -$63.2M | $77.9M | -$31.3M | -$142.0M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 17.5% | 75.1% | 287.7% | 184.2% | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 30, 2026 | 65.4M | +14.5% | SEC |
| Jul 30, 2026 | 64.5M | +17.8% | SEC |
| Apr 30, 2026 | 62.3M | +14.1% | SEC |
| Feb 28, 2026 | 59.2M | +9.4% | SEC |
| Oct 31, 2025 | 57.1M | +7.8% | SEC |
| Jul 31, 2025 | 54.8M | +4.1% | SEC |
| Apr 30, 2025 | 54.6M | +4.8% | SEC |
| Feb 28, 2025 | 54.1M | +16.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.